454910.KO

T3

Doosan Robotics Inc.

Next est. report · BMO

Humanoid '25: Industrial Automation OEMsHumanoid '25: Learned Memory & Interfacing
Loading…
Key Reported Metrics, Reratings Triggers & Results3 rows

Provides forward visibility into future revenue and confirms pipeline strength. Growth here demonstrates sustained customer investment in robotics, crucial for

Key reported metricsRerating thresholds
MetricLast periodWhy it mattersWhat's needed for reratingRerating contextEarnings date
Automation Solutions Order Backlog (Americas)N/A

Provides forward visibility into future revenue and confirms pipeline strength. Growth here demonstrates sustained customer investment in robotics, crucial for long-term performance and investor confidence, especially in the strategic North American market.

The Automation Solutions Order Backlog (Americas) needs to demonstrate robust growth, ideally exceeding $16.8 million (a 25% sequential increase from the reported Q1 2026 backlog of $13.5 million). A year-over-year growth rate of at least 30% would also signal strong momentum, aligning with the company's aggressive North American expansion and the broader industrial automation market rebound.

Hitting this threshold would validate Doosan Robotics' strategic focus on the high-growth North American market and the success of its AI-driven automation solutions. It confirms strong customer demand, crucial for long-term revenue visibility and investor confidence in the 'Humanoid '25' thesis, driving a positive rerating by signaling market adoption and competitive strength.

Total Revenue189.7%

Indicates market adoption and demand for collaborative robots. Strong growth validates the 'Humanoid '25' thesis of accelerating automation and economic viability, signaling robust market expansion and investor confidence.

Doosan Robotics Inc. needs to report Q2 2026 Total Revenue growth of at least 100% year-over-year, leading to an upward revision of the full-year 2026 revenue guidance to above 75 billion KRW.

Hitting this threshold validates the 'Humanoid '25' thesis by demonstrating accelerating market adoption and demand for Doosan's collaborative and AI-powered robots. It signals successful execution of their North American expansion and AI solution strategy, improving investor confidence in their competitive position and long-term growth trajectory, potentially leading to a higher valuation multiple.

Operating Marginapprox. 0% (change in operating loss YoY)

Reflects profitability amidst competition and supply chain dynamics. Improvement or stability is crucial for sustainable growth, validating economic viability from AI and expansion investments, and is key for rerating towards profitability.

For the stock to rerate higher, Doosan Robotics needs to demonstrate a clear and accelerated trajectory towards profitability. For the upcoming Q2 2026 earnings, a significant reduction in the operating loss, ideally surpassing analyst expectations for loss contraction, would be a positive catalyst. For a sustained rerating, the company must provide a credible outlook and show tangible progress towards achieving a positive operating margin of at least 1-3% by 2027, aligning with its stated goal of a 'turnaround to profitability'.

Achieving a positive operating margin validates Doosan Robotics' business model and its ability to generate sustainable profits. This signals effective cost management and pricing power, directly supporting the 'Humanoid '25' thesis of accelerating automation. It would significantly boost investor confidence, leading to a re-evaluation of valuation and competitive position.